MedPath

Ensayo clínico controlado y aleatorizado para evaluar el efecto de los gabapentinoides sobre el dolor agudo postoperatorio en pacientes quemados

Conditions
Postoperative pain in burned patients with a burn excision area between 2 and 12 % of total body surface area.
Registration Number
EUCTR2007-006182-32-ES
Lead Sponsor
Anaesthesiology Department. Universitary Hospital Vall d'Hebron, Barcelona.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Both sexes
Age between 18 and 70 years old
Admision to the Burn Unit of Hospital Universitari Vall d'Hebron, Barcelona, for surgical treatment
Burn excision between 2 and 12 % of body surfece area under general anaesthesia
Estimated length of stay longer than three days
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Inability to operate a PCA device
Neurological deficits
Psychiatric disorders
Opioid abuse
Pregnancy
Use of local anaesthetics
Daily NSAID intake
Renal failure
Allegy to the study medication

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: Efficacy of gabapentin and pregabalin on opioid consumption during the 24 h after surgery in burned patients with a burn excision area between 2 and 12 % of total body surface area.;Secondary Objective: VAS pain evaluation in the immediate postoperative period (24 hours)<br>Comparison of gabapentinoids effect to dexketoprofen effect on postoperative analgesia in burned patients<br>Side effects evaluation<br>;Primary end point(s): Opioid consumption during the first 24 hours following surgery
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath